Kailera TherapeuticsKLRA.OValuation Analysis

As of Oct 16, 2026, Kailera Therapeutics (KLRA.O) trades at a P/E of N/A, P/B of 1.31x, P/S of N/A, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 14th percentile over the trailing 10Y window (vs. 14th percentile over 3Y); P/S historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data).
Cross-sectional valuation: its P/B ranks at the 32nd percentile within its industry and the 40th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/B percentile sits lower within its industry than across the market as a whole — relatively cheaper next to direct peers. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Kailera Therapeutics operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.